Loading...
XASE
IBO
Market cap6mUSD
Jul 09, Last price  
0.60USD
1D
0.18%
1Q
17.65%
IPO
-74.25%
Name

Impact Biomedical Inc

Chart & Performance

D1W1MN
XASE:IBO chart
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
Net income
CFO

Profile

Impact BioMedical Inc. engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. It provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. The company also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, it develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. The company was incorporated in 2018 and is based in Houston, Texas.
IPO date
Sep 16, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

No data to show